All In Biotech

Drug Trial Radar · NCT05915442

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Phase II Single Arm Study Testing SBRT, Adenosine Signaling Modulation (AB680, AB928), and Immune Checkpoint Inhibition (AB122) for Men With Hormone Sensitive Oligometastatic Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

23

Planned (sponsor's estimate)

Start

Jul 1, 2023

Primary completion

Dec 1, 2026

Study completion Dec 2028

Sponsor

Lead sponsor
Catherine SpinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Arcus Biosciences, Inc.
First posted
Jun 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and effectiveness of a combination of study drugs including zimberelimab, etrumadenant, and quemliclustat in combination with metastasis-directed irradiation in men with hormone sensitive oligometastatic prostate cancer. The study aims to test the hypothesis that targeted inhibition of the adenosine signaling axis (quemliclustat (CD73 antagonist) + etrumadenant (A2AR/A2BR antagonist)) and immune checkpoint inhibition (zimberelimab, α-PD-1) in combination with metastasis-directed stereotactic body radiation therapy (SBRT) will improve local control, progression-free survival (PFS), and hormone therapy-free survival and mitigate immunosuppressive changes to the tumor microenvironment (TME), compared to SBRT alone.

Conditions

  • Oligometastatic Prostate Cancer

Interventions

  • QuemliclustatDrug

    100mg IV once every two weeks

  • EtrumadenantDrug

    150 mg orally (PO) once a day (QD)

  • ZimberelimabDrug

    240 mg IV once every two weeks starting within 1 week of completing metastasis-directed SBRT

  • Stereotactic Body Radiation TherapyRadiation

    Standard of care metastasis-directed hypofractionated radiotherapy treatment starting 4 weeks (+/- 1 week) of starting Etrumadenant and Quemliclustat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biochemical recurrence-free survival at 12-monthsTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Columbia University Irving Medical Center / NewYork-Presbyterian Hospital

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.